Related Experiment Video
Updated: Jun 4, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
Published on: June 4, 2012
Use of daptomycin in complicated cases of infective endocarditis
1Department of Clinical Microbiology and Infection Control, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK. ira.das@uhb.nhs.uk
Abstract:
Infective endocarditis (IE) is a serious form of infection with a high mortality. Medical management can be a challenge because of organ dysfunction, lack of clinical response or allergy to the recommended antibiotics. Daptomycin is a lipopeptide antibiotic with a potent bactericidal activity against Gram-positive bacteria. There are limited data on the use of daptomycin in complicated cases of IE. We aim to report our experience of daptomycin use in complicated cases of IE through a prospective observational study (from 1 October 2008 to 30 September 2009). Daptomycin was prescribed for cases that were either unresponsive or allergic to the standard therapy. Clinical characteristics and outcomes were reviewed. Success was defined as clinical improvement accompanied with the resolution of laboratory markers of sepsis and continuation of the above findings for at least 8 weeks after the end of therapy. Eight cases were evaluable. Native and prosthetic valves were involved in equal proportions. The range of organisms was wide: Staphylococcus aureus, two cases; S. epidermidis, two cases; streptococci, two cases; and Enterococcus faecalis, two cases. The median duration of therapy was 42 days. All patients were successfully treated. Daptomycin was well tolerated. Daptomycin is useful in the management of complicated cases of IE.
Insights
Daptomycin effectively treated complicated infective endocarditis (IE) in patients unresponsive or allergic to standard antibiotics. This study shows daptomycin is a safe and useful option for challenging IE cases.
Area of Science:
- Infectious Diseases
- Pharmacology
Background:
- Infective endocarditis (IE) presents significant mortality and treatment challenges.
- Standard antibiotic therapy may fail due to resistance, organ dysfunction, or allergies.
- Limited data exists on daptomycin's efficacy in complex IE cases.
Purpose of the Study:
- To evaluate the effectiveness and safety of daptomycin in complicated IE cases.
- To assess daptomycin's utility when standard treatments are contraindicated or ineffective.
Main Methods:
- Prospective observational study from October 2008 to September 2009.
- Daptomycin administered to patients with IE unresponsive or allergic to standard therapy.
- Clinical characteristics and outcomes were reviewed, with success defined by clinical and laboratory resolution for 8 weeks post-therapy.
Main Results:
- Eight evaluable cases included native and prosthetic valve IE.
- Involved pathogens included Staphylococcus aureus, S. epidermidis, streptococci, and Enterococcus faecalis.
- All patients achieved successful treatment outcomes with daptomycin, which was well tolerated.
Conclusions:
- Daptomycin demonstrates utility in managing complicated infective endocarditis.
- It offers a viable treatment option for IE patients with limited therapeutic choices.
Related Concept Videos
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Endocarditis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Diphtheria
Cardiomyopathy II: Dilated Cardiomyopathy